AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 1.95 |
|---|---|
| Change | -0.175 8.974% |
| 52 W H/L (in USD) | 3.400/0.973 |
| EBITDA (in USD) | -147.367M |
| PE Ratio | -- |
| Volume | 1691337 |
| Diluted Eps TTM | -1.39 |
| Total Assets (in USD) | 293.237M |
|---|---|
| Total Liabilities (in USD) | 262.588M |
| Revenue TTM (in USD) | 21.045M |
| Cash (in USD) | 65.802M |
| Market Cap (in USD) | 271.492 M |
| Revenue Per Share TTM | 0.204 |
| Gross Profit TTM (in USD) | -102.02M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
415 231 5660
Employees: 103
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Tillman Ulf Gerngross Ph.D. | Co-Founder & Chairman | 1964 |
| 2. | Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director | 1956 |
| 3. | Dr. Sara Kenkare-Mitra Ph.D. | Pres and Head of R&D | 1968 |
| 4. | Mr. Calvin Yu | VP of Fin. | 1976 |
| 5. | Dr. Marc Grasso M.D. | Chief Financial Officer | 1974 |
| 6. | Mr. Peter Heutink Ph.D. | Chief Scientific Officer | NA |
| 7. | Michelle Corral | VP of Communications & Investor Relations | NA |
| 8. | Ms. Danielle Pasqualone J.D., Ph.D. | Gen. Counsel | NA |
| 9. | Erica Jefferson | VP of Communications & Public Affairs | NA |
| 10. | Ms. Clare Hunt M.B.A. | Chief People Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -142.761M | -118.921M | -125.179M | -130.056M | -36.329M |
| Minority Interest | - | - | - | - | - |
| Net Income | -142.929M | -119.049M | -130.391M | -133.31M | -28.014M |
| Selling General Administrative | 53.987M | 59.615M | 56.687M | 61.033M | 55.038M |
| Gross Profit | 11.384M | 100.558M | 88.214M | 133.617M | 207.085M |
| Reconciled Depreciation | 9.661M | 8.841M | 8.703M | 8.472M | 8.315M |
| Ebit | -142.761M | -144.997M | -151.74M | -146.306M | -45.675M |
| Ebitda | -133.1M | -136.156M | -142.892M | -137.834M | -37.36M |
| Depreciation And Amortization | 9.661M | 8.841M | 8.848M | 8.472M | 8.315M |
| Operating Income | -145.807M | -144.997M | -151.74M | -137.834M | -37.36M |
| Other Operating Expenses | 166.852M | 245.555M | 248.802M | 271.451M | 244.445M |
| Interest Expense | - | - | - | -16.25M | 8.315M |
| Tax Provision | 0.168M | 0.128M | 4.267M | 3.254M | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | 0.168M | 0.128M | 5.212M | 3.254M | -8.315M |
| Total Revenue | 21.045M | 100.558M | 97.062M | 133.617M | 207.085M |
| Total Operating Expenses | 157.191M | 245.555M | 239.954M | 271.451M | 244.445M |
| Cost Of Revenue | 9.661M | 8.841M | 8.848M | - | - |
| Total Other Income Expense Net | 3.046M | 26.076M | 26.561M | 7.778M | 1.031M |
| Net Income From Continuing Ops | -142.929M | -119.049M | -141.385M | -133.31M | -36.329M |
| Net Income Applicable To Common Shares | - | - | - | -133.31M | -36.329M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 293.237M | 468.303M | 621.827M | 787.648M | 814.658M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 10.428M | 11.42M | 16.946M | 10.997M | 7.071M |
| Total Liab | 262.588M | 341.503M | 487.669M | 573.206M | 513.934M |
| Total Stockholder Equity | 30.649M | 126.8M | 134.158M | 214.442M | 300.724M |
| Other Current Liab | 51.706M | 90.427M | 82.736M | -14.901M | -55.129M |
| Common Stock | 0.011M | 0.009M | 0.008M | 0.008M | 0.008M |
| Capital Stock | 0.011M | 0.009M | 0.008M | 0.008M | 0.008M |
| Retained Earnings | -972.056M | -829.127M | -710.078M | -579.687M | -446.377M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 7.881M | 7.046M |
| Cash | 65.802M | 33.021M | 74.555M | 154.323M | 329.152M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 69.503M | 125.059M | 177.948M | 45.578M | 48.218M |
| Current Deferred Revenue | 6.684M | 23.663M | 82.975M | 48.231M | 90.803M |
| Net Debt | -29.569M | 9.498M | -35.637M | -110.996M | -281.551M |
| Short Term Debt | 9.422M | 8.754M | 8.462M | 8.059M | 7.795M |
| Short Long Term Debt | 0.366M | - | - | - | - |
| Short Long Term Debt Total | 36.233M | 42.519M | 38.918M | 43.327M | 47.601M |
| Other Stockholder Equity | 1002.528M | 955.657M | 844.044M | 798.696M | 748.036M |
| Property Plant Equipment | - | - | - | 53.332M | 27.33M |
| Total Current Assets | 266.452M | 424.817M | 565.807M | 726.435M | 749.713M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 190.222M | 380.376M | 474.306M | 558.528M | 406.099M |
| Net Receivables | - | - | - | 2.587M | 7.391M |
| Long Term Debt | 9.323M | 9.389M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.691M | 2.215M | 3.775M | 4.189M | 4.749M |
| Accumulated Other Comprehensive Income | 0.166M | 0.261M | 0.184M | -4.575M | -0.943M |
| Non Currrent Assets Other | 2.232M | 6.39M | 7.418M | 7.881M | 7.046M |
| Non Current Assets Total | 26.785M | 43.486M | 56.02M | 61.213M | 64.945M |
| Capital Lease Obligations | 26.544M | 33.13M | 38.918M | 43.327M | 47.601M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 196.638M | 107.131M | 102.228M | -159.014M | -46.416M |
| Total Cashflows From Investing Activities | 196.597M | 107.131M | 101.918M | -159.014M | -49.663M |
| Total Cash From Financing Activities | 20.215M | 81.54M | 2.55M | 4.514M | 30.295M |
| Net Income | -142.929M | -119.049M | -130.391M | -133.31M | -36.329M |
| Change In Cash | 32.781M | -41.234M | -79.694M | -174.829M | 279.183M |
| Begin Period Cash Flow | 34.867M | 76.101M | 155.795M | 330.624M | 51.441M |
| End Period Cash Flow | 67.648M | 34.867M | 76.101M | 155.795M | 330.624M |
| Total Cash From Operating Activities | -184.031M | -229.905M | -184.162M | -20.329M | 298.551M |
| Depreciation | -0.861M | 8.841M | 8.848M | 8.472M | 8.315M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -2.587M | - | - |
| Sale Purchase Of Stock | - | - | - | - | 30.295M |
| Other Cashflows From Financing Activities | 0.217M | 1.043M | 2.55M | 1.455M | 30.295M |
| Capital Expenditures | 0.041M | 1.255M | 2.381M | 4.117M | 3.247M |
| Change In Working Capital | -74.057M | -146.986M | -90.147M | 59.526M | 283.681M |
| Other Non Cash Items | 7.158M | -12.174M | -15.27M | -1.163M | 2.099M |
| Free Cash Flow | -184.072M | -231.16M | -186.543M | -24.446M | 295.304M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 2541322 |
| 2. | Fidelity Select Biotechnology | 3 months ago | 2221104 |
| 3. | iShares Russell 2000 ETF | 2 months ago | 2154274 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 1037527 |
| 5. | Fidelity Small Cap Index | 4 months ago | 781483 |
| 6. | iShares Russell 2000 Value ETF | 2 months ago | 714453 |
| 7. | Vanguard VIF Small Co Gr | 5 months ago | 701545 |
| 8. | BlackRock Advantage Small Cap Core Instl | 3 months ago | 643388 |
| 9. | Vanguard Strategic Small-Cap Equity Inv | 5 months ago | 628627 |
| 10. | Vanguard Explorer Inv | 5 months ago | 595341 |
| 11. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 521977 |
| 12. | Fidelity Extended Market Index | 3 months ago | 491836 |
| 13. | Schwab US Small-Cap ETF™ | 2 months ago | 449715 |
| 14. | Vanguard Russell 2000 ETF | 2 months ago | 449350 |
| 15. | Russell 2000 Equity Index Fund B | 5 months ago | 417919 |
| 16. | TD Health Sciences - I | 11 months ago | 325869 |
| 17. | State St Russell Sm Cap® Indx SL Cl I | 3 months ago | 293904 |
| 18. | Multi-Manager Small Cap Eq Strat Inst | 2 months ago | 271190 |
| 19. | Mackenzie GQE US Small Cap F8 | 4 months ago | 265244 |
| 20. | Xtrackers MSCI World Swap ETF 1C | 5 months ago | 264871 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Foresite Capital Management IV, LLC | 5 months ago | 3887200 |
| 2. | TCG Crossover Management, LLC | 5 months ago | 10000000 |
| 3. | BlackRock Inc | 8 months ago | 7197973 |
| 4. | Vanguard Group Inc | 5 months ago | 6908054 |
| 5. | Merck & Co Inc | 8 months ago | 3545719 |
| 6. | 683 Capital Management LLC | 5 months ago | 3350000 |
| 7. | Balyasny Asset Management LLC | 5 months ago | 3265575 |
| 8. | D. E. Shaw & Co LP | 5 months ago | 2365151 |
| 9. | FMR Inc | 5 months ago | 2231171 |
| 10. | T. Rowe Price Associates, Inc. | 8 months ago | 2185032 |
| 11. | Jacobs Levy Equity Management, Inc. | 5 months ago | 2173202 |
| 12. | Ikarian Capital, LLC | 5 months ago | 2082606 |
| 13. | Geode Capital Management, LLC | 5 months ago | 2075220 |
| 14. | Kynam Capital Management, LP | 5 months ago | 2000000 |
| 15. | State Street Corp | 8 months ago | 1734679 |
| 16. | Renaissance Technologies Corp | 5 months ago | 1543650 |
| 17. | Medici Capital LLC | 5 months ago | 1500520 |
| 18. | Millennium Management LLC | 5 months ago | 1332914 |
| 19. | Euclidean Capital LLC | 5 months ago | 1307858 |
| 20. | Marshall Wace Asset Management Ltd | 5 months ago | 1166817 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...